Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05471310
Other study ID # LB_03/17/22
Secondary ID
Status Completed
Phase
First received
Last updated
Start date March 15, 2021
Est. completion date June 30, 2022

Study information

Verified date July 2022
Source Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Ataxia-telangiectasia (A-T) is a multisystem auto-somal recessive disorder linked to the A-T mutated gene (ATM) on chromosome 11q22-23, and characterized by progressive neural degeneration, immunodeficiency, and progressive ocular motor dysfunction. In previous studies, the quantitative description of the ocular motor deficits from clinical examination was limited to various defects in saccade and gaze control, dysmetric saccades, impairments of smooth pursuit, gaze holding, convergence, vestibular and optokinetic nystagmus slow phases, and cancellation of the vestibulo-ocular reflex. The aim of our research is to add existing findings with quantitative description of oculomotor patterns in A-T patients using videooculography (VOG).


Recruitment information / eligibility

Status Completed
Enrollment 5
Est. completion date June 30, 2022
Est. primary completion date March 31, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 8 Years to 17 Years
Eligibility Inclusion Criteria: - confirmed diagnosis of ataxia telangiectasia, - informed consent, - stay at the Clinical Research Rehabilitation Center "Russkoe Pole" for 14 days. Exclusion Criteria: - epilepsy, - poor visual acuity, inability to percept from a computer monitor, - inability to hold head and posture satisfactory to perform the tasks, - difficulty to obtain adequate recordings due to corrective lenses, - visual field defects.

Study Design


Locations

Country Name City State
Russian Federation Clinical Rehabilitation Research Center "Russkoe pole" Chéjov

Sponsors (1)

Lead Sponsor Collaborator
Federal Research Institute of Pediatric Hematology, Oncology and Immunology

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type Measure Description Time frame Safety issue
Primary Gaze holding task A fixation task in which the subject will require to look at a target-a green circle (diameter ~1) sequentially presented at eccentric (15 rightward and leftward, 8 upward and downward) positions, each eccentric position being sustained for 20 s. Gaze-holding score will be assessed for each circle by approximating the gaze position coordinates by the least squares method to obtain the best correspondence using the fit function. The areas of the obtained ellipses, reflecting the spread of gaze position coordinates, will be determined for each of the four circle positions in each subject. Areas will be expressed in square visual degrees (sq. deg.) baseline, during the intervention-rehabilitation course (once)
Primary Visual search task Ten black circles (diameter ~1) will be presented on the monitor distributed pseudorandomly over the screen. Subjects will be instructed to count silently the number of points and give a verbal response. Study parameters: the performance time, the number of fixations, their durations, the total length of the scanning trajectory, and the saccade amplitude. baseline, during the intervention-rehabilitation course (once)
Primary Visually guided saccade task The subject will be required to follow a target jumping their gaze from one corner of the square to the next as quickly as possible as soon as a circle appeared; saccades will be required in order to do this (An image of a square with side length 10° will be presented on the monitor and a red circle (diameter ~1°) appeared in the corners sequentially in the clockwise direction.) Study parameters: the total number of saccades completed, the proportions of relatively accurate (A in the range 8.5-11.5°), hypometric (short, A < 8.5°), and hypermetric (long, A > 11.5°), and corrective saccades (occurring only after dysmetric saccades, 1.5° < A < 5°); baseline, during the intervention-rehabilitation course (once)
Secondary Scale for the assessment and rating of ataxia A clinical scale that is based on a semi-quantitative assessment of cerebellar ataxia on an impairment level. baseline, during the intervention-rehabilitation course (once)
See also
  Status Clinical Trial Phase
Completed NCT02345135 - Susceptibility to Infections in Ataxia Telangiectasia N/A
Active, not recruiting NCT04991701 - A National Retrospective Population Based Cohort Study of the Natural History of Ataxia Telangiectasia
Active, not recruiting NCT05531890 - Comparative Bioavailability of Betamethasone Oral Solution Metered Spray (GTX-102) in Healthy Subjects Phase 1
Recruiting NCT05692596 - The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics
Completed NCT05252819 - Whole Body MRI for Cancer Surveillance in A-T
Recruiting NCT03357978 - Susceptibility to Infections, Tumor Risk and Liver Disease in Patients With Ataxia Telangiectasia N/A
Withdrawn NCT02309632 - Pancreatic Cancer Screening of High-Risk Individuals in Arkansas N/A
Not yet recruiting NCT06193200 - To Evaluate the Effects of EryDex in Patients With A-T Phase 3
Not yet recruiting NCT06324877 - Ataxia-telangiectasia: Treating Mitochondrial Dysfunction With Nicotinamide Riboside N/A
Not yet recruiting NCT01075438 - Immunogenicity of Pneumococcal Vaccines in Ataxia-telangiectasia Patients N/A
Completed NCT03962114 - Effects of Vitamin B3 in Patients With Ataxia Telangiectasia Phase 2
Completed NCT04513002 - Ataxia-telangiectasia: Treating Mitochondrial Dysfunction With a Novel Form of Anaplerosis Phase 2
Active, not recruiting NCT04870866 - NAD Supplementation to Prevent Progressive Neurological Disease in Ataxia Telangiectasia Phase 2
Recruiting NCT03563053 - Open-label, Long-term, Extension Treatment Using Intra-Erythrocyte Dexamethasone Sodium Phosphate in Patients With Ataxia Telangiectasia Who Participated in the IEDAT-02-2015 Study Phase 3
Recruiting NCT05692622 - Home-based Complex Intervention for Children With Ataxia Telangiectasia N/A
Recruiting NCT04037189 - Treatment of Leukemia and Lymphoma in Children With Ataxia Telangiectasia
Not yet recruiting NCT04887311 - MBM-01 (Tempol) for the Treatment of Ataxia Telangiectasia Phase 2
Active, not recruiting NCT00951886 - The Validity of Forced Expiratory Maneuvers in Ataxia Telangiectasia Studied Longitudinally N/A
Recruiting NCT03759678 - N-Acetyl-L-Leucine for Ataxia-Telangiectasia (A-T) Phase 2
Recruiting NCT01052623 - Status of Growth Hormone/ Insulin-like Growth Factor-1 (GH/IGF-1) Axis and Growth Failure in Ataxia Telangiectasia (AT) Phase 4